Acadia Healthcare Company stock has seen its price target recalibrated, with analysts trimming assumptions around the discount rate while keeping fair value and revenue growth expectations largely intact. This shift reflects a more nuanced view of risk and future cash flows as the market digests softer Medicaid trends and higher bad debt against a still constructive long term growth story. Stay tuned to learn how you can monitor these evolving assumptions and keep ahead of the changing narrative around Acadia Healthcare’s valuation.

Stay updated as the Fair Value for Acadia Healthcare Company shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Acadia Healthcare Company.

???? Bullish Takeaways

RBC Capital continues to rate Acadia Healthcare shares as Outperform, signaling that, despite recent headwinds, the firm still sees the risk reward skew as attractive at current levels.

The decision to maintain a positive rating while revising the model after Q3 implies that RBC still has confidence in Acadia's longer term execution and growth prospects, even as near term assumptions are recalibrated.

???? Bearish Takeaways

RBC Capital lowered its price target on Acadia Healthcare to $22 from $28, a meaningful reset that reflects softer expectations for value creation versus prior forecasts.

The firm cites weaker Medicaid volume and increased bad debt expense as key drivers of the latest quarter's underperformance and the reduced 2025 outlook, highlighting pressure on both revenue visibility and earnings quality.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Engine Capital has accumulated roughly a 3% stake in Acadia Healthcare, becoming one of its 10 largest shareholders and publicly pressing the board for a refresh, operational streamlining, potential asset sales, and larger share repurchases amid ongoing DOJ and SEC investigations into patient care and billing practices.

Acadia lowered its full year 2025 revenue guidance to $3.28 billion to $3.30 billion, citing expected PLGL charges of $4 million to $6 million in the fourth quarter and rate pressure tied to shifting macroeconomic and policy conditions.

Activist investors Khrom Capital Management and Engine Capital have each sent letters urging Acadia’s board to conduct a formal review of strategic alternatives, implement governance reforms, revamp executive compensation, cut costs, and prioritize capital returns to address what they characterize as long standing underperformance and governance failures.

The company completed a $50.02 million share repurchase program, buying back about 1.7 million shares, or roughly 1.84% of shares outstanding, though it did not repurchase additional shares under the authorization in the most recent quarter.

Fair Value: Unchanged at an implied intrinsic value of approximately $25.32 per share, indicating no shift in the core long term valuation estimate.

Discount Rate: Fallen slightly from about 8.16% to roughly 8.10%, reflecting a modest reduction in the perceived risk profile or required return.

Revenue Growth: Essentially unchanged at approximately 5.88%, suggesting stable expectations for top line expansion.

Net Profit Margin: Stable at around 4.67%, indicating no material revision to long term profitability assumptions.

Future P/E: Edged down marginally from about 15.93x to roughly 15.90x, implying a slightly lower valuation multiple applied to forward earnings.

Narratives are investor written stories that connect what a company does with what its numbers could look like in future, from revenue and earnings to margins and fair value. On Simply Wall St’s Community page, used by millions of investors, Narratives link the business story to a financial forecast so you can compare Fair Value to the current share price and decide when to buy or sell. They update dynamically as new news or earnings arrive, keeping your view of a company continuously refreshed.

Head over to the Simply Wall St Community and follow the Narrative on Acadia Healthcare Company to stay on top of the evolving story:

How activist pressure, potential board changes, and capital allocation shifts could unlock upside from today’s price.

Whether projected revenue growth to $4.1b, margin expansion, and EPS of $3.49 by 2028 can justify analysts’ $30.43 price target.

What ongoing Medicaid headwinds, legal costs, and underperforming facilities might mean for long term risk and fair value.

Read the full Acadia Healthcare Company Narrative on Simply Wall St

Curious how numbers become stories that shape markets? Explore Community Narratives

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ACHC.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com